Share Price:

APNASPENAspen Pharmacare Hldgs13615265 (1.99%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Key ARV Products Viread® and Truvada® Registered by MCC

JSE listed Aspen, a leading global manufacturer and distributor of anti-retroviral (ARV) medicines, today announced that it has been granted certification from the Medicines Control Council of South Africa (MCC) to manufacture and distribute the two key ARV products Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) in the South African market.… Continue reading Key ARV Products Viread® and Truvada® Registered by MCC

Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Co Cork, Ireland (April 4th, 2007) – Tibotec Pharmaceuticals Ltd. has signed a royalty-free, non-exclusive license agreement with Aspen of South Africa. Aspen will register, package and distribute the protease inhibitor PREZISTA™ (darunavir, DRV) in sub-Saharan Africa. Tibotec has selected Aspen because of the company’s extensive African distribution network and pioneering endeavors in enhancing access… Continue reading Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Aspen and Strides enter into broad and strategic partnership

Johannesburg South Africa, and Bangalore, India: Aspen Pharmacare (Aspen), Africa’s largest pharmaceutical manufacturer and the largest generics manufacturer in the southern hemisphere, has entered into a series of transactions with Bangalore-based Strides Arcolab Limited (Strides), one of India’s largest exporters of pharmaceutical products. The transactions comprise: the acquisition by Aspen of 50% of Strides’ Latin… Continue reading Aspen and Strides enter into broad and strategic partnership

Aspen records 15% increase in revenue

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded positive results for the period ended December 2006. Revenue increased by 15 percent to R1,936 billion (R1.687 billion). Net profit after tax rose 15 percent to R332 million (R288.5 million). Earnings per share increased by 13 percent to 95,3 cents (84,5 cents). Headline… Continue reading Aspen records 15% increase in revenue

Appointment of Alternate Director

Aspen has appointed Derek Thomas, BCom (Finance and Economics); BCom (Hons) (Economics); MCOM (Economics); MSc (Economics), as an alternate director to Pasco Dyani with effect from 6 February 2007. Since 2000, Derek has served as CEO of CEPPWAWU Investments (Pty) Ltd, a broad based black economic empowerment investment company (wholly owned by a Trust formed… Continue reading Appointment of Alternate Director

Once-offs results in 235% increase in HEPS

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has announced impressive results for the financial year ended June 30, 2006. These are the first set of annual results reported under International Financial Reporting Standards (IFRS). Headline earnings per share (HEPS) grew by 235 percent to 185.5 cents (144.7 cents). Revenue increased by 23… Continue reading Once-offs results in 235% increase in HEPS

Aspen 3rd in FM 2006 Top Companies

Aspen was ranked third in the June 2006 Financial Mail Top Companies survey. Companies are ranked based on consistent performance for five years. Aspen wasn’t on the radar screen a few years ago; now it’s in third position and has a market capitalization in excess of R14 billion. Aspen’s share delivered a highly credible 112%… Continue reading Aspen 3rd in FM 2006 Top Companies

Dr. Judy Dlamini appointed chairman designate at Aspen

Dr Judy Dlamini will succeed Archie Aaron as chairman of the board of directors of Aspen Pharmacare Holdings Limited (“Aspen”) after Aspen’s annual general meeting of shareholders which is scheduled to take place in November 2007. Archie Aaron has decided to step down as chairman having served in this position since 1999. He will remain… Continue reading Dr. Judy Dlamini appointed chairman designate at Aspen

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: